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Abstract
Background: IgM multiple myeloma is rare disorder, which has clinical, laboratory and radiological
manifestations that are consistent with both multiple myeloma and Waldenstrom's
macroglobulinaemia.
Case presentation: An 83 years Welsh lady presented with clinical and radiological features
consistent with spinal cord compression. Further investigations confirmed the diagnosis of IgM
multiple myeloma. Following localized radiotherapy and five courses of melphalan and
prednisolone, the patient achieved partial remission of her myeloma. Later on, the patient had
disease progression in the form of rising serum IgM level and the development of multiple
plasmacytomas. She was treated with thalidomide, cyclophosphamide, dexamethasone and
radiotherapy, which resulted in the control of her disease for one year. To our knowledge, this is
the second case of IgM myeloma presenting with a plasmacytoma and the first case of IgM myeloma
presenting with cord compression caused by plasmacytomas.
Conclusion: Unlike other types of multiple myeloma IgM myeloma is rarely complicated by
plasmacytomas. However, spinal cord compression caused by plasmacytomas in this type of
myeloma is extremely rare. Nevertheless, the same lines of management, e.g. cytotoxic
chemotherapy and local radiotherapy that are applied to other types of myeloma can be
successfully utilized.
Background
Multiple myeloma (MM) is a B-cell lymphoid malignancy
characterized by malignant clonal proliferation and accu-
mulation of plasma cells that secrete paraproteins. Less
than 1% of the cases are non-secretory. The incidence of
this disorder is 3 per 100,000 per annum and the median
age at diagnosis 60–65 years. In patients less than 40 years
of age, the incidence of the disease is less than 2% [1,2].
The International Myeloma Working Group (IMWG) has
reviewed the criteria for diagnosis and classification with
the aim of producing simple, easily used definitions based
on routinely available investigations. In monoclonal gam-
mopathy of undetermined significance (MGUS), the
monoclonal protein is < 30 g/l and the bone marrow
clonal cells < 10% with no evidence of MM, other B-cell
proliferative disorders or amyloidosis. In asymptomatic
or smoldering myeloma, the M-protein is at least 30 g/l
and/or the bone marrow clonal cells are at least 10% but
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there is no related organ tissue impairment or end-organ
damage, which is typically manifested by increased cal-
cium, renal insufficiency, anemia or bone lesions attrib-
uted to the plasma cell proliferative process. The diagnosis
of symptomatic myeloma requires the presence of evi-
dence of end-organ damage. However, non-secretory
myeloma is characterized by the absence of M-protein in
the serum and urine, bone marrow plasmacytosis and end
organ-damage. Nevertheless, solitary plasmacytoma of
bone, extramedullary plasmacytoma and multiple solitary
plasmacytomas are still defined as distinct entities [1,2].
Case presentation
An eighty three years old Welsh lady presented to the acci-
dent and emergency at Ysbyty Gwynedd Hospital in Wales
with history of worsening weakness and tingling in the
left upper arm for six weeks. Clinical examination showed
brisk reflexes in the left upper limb, global weakness and
increased tone in the same limb. An urgent MRI scan (Fig
1) revealed two soft tissue masses, one compressing the
spinal cord at C6/C7 level and the other projecting into
the cord and causing significant spinal cord compression
at T8 level (Fig 1). Full blood count and biochemistry
showed no abnormalities. Protein electrophoresis
revealed monoclonal gammopathy with IgM paraprotein.
Skeletal survey showed two lytic lesions. Bone marrow tre-
phine biopsy showed infiltration with 20% of plasma
cells. Immunohistochemistry revealed positive CD38 and
negative CD20, CD19, CD56 and CD45 (Fig 2). A biopsy
was not taken from the soft tissues described above due to
technical difficulties. After establishing the diagnosis of
IgM MM, the patient was commenced on radiotherapy,
followed by five courses of melphalan and prednisolone.
Disease progression was monitored by a series of protein
electrophoresis assays, which showed a reduction in the
paraprotein from 36 g/l at diagnosis to 6.5 g/l. The patient
remained well for 7 months until a periumbilical mass 5
× 5 cm infiltrating the skin appeared. Consequently,
biopsy of the lesion showed 56 percent infiltration by
plasma cells. Computerized tomography scans revealed
MRI scan shows two soft tissue masses compress the spinal  cord at levels T8 and C6/C7 Figure 1
MRI scan shows two soft tissue masses compress the 
spinal cord at levels T8 and C6/C7.
Bone marrow Trephine biopsy showing CD38 positive cells  {black-brown coloured}. Both figures were taken at diagnosis Figure 2
Bone marrow Trephine biopsy showing CD38 posi-
tive cells {black-brown coloured}. Both figures were 
taken at diagnosis.Cases Journal 2008, 1:207 http://www.casesjournal.com/content/1/1/207
Page 3 of 4
(page number not for citation purposes)
multiple masses having different sizes infiltrating kidneys
and right breast. Then the patient was treated with CTD
regimen (cyclophosphamide, thalidomide and dexameth-
asone) followed by palliative radiotherapy. Currently, the
patient is still alive and well more than one year after
receiving the last session of palliative radiotherapy.
Discussion
MM syndromes have specific laboratory findings and are
associated with monoclonal proliferation of plasma cells
that usually secret monoclonal proteins, ultimately lead-
ing to bone destruction. Extramedullary tumors are not
rare manifestations of MM. However, soft tissue is the
commonest site involved. Having higher serum C-reactive
protein and lactic dehydrogenase levels and the presence
of a more advanced stage for international staging system
(ISS), anemia and extramedullary tumors are the main
poor prognostic factors of MM [3,4]. Waldenstrom's mac-
roglobulinaemia (WM) is a B-cell lymphoproliferative
disorder characterized primarily by the infiltration of lym-
phoplasmacytic cells into the bone marrow and the dem-
onstration of IgM monoclonal gammopathy [5-8].
MM with IgM gammaglobulin is a rather distinct subtype
of MM displaying clinical and pathologic features of both
MM and WM [5]. It is a very rare disease that accounts for
approximately 0.5 percent of all MMs. It usually presents
with the same signs and symptoms as other types of mye-
loma and should be distinguished from WM based on
clinical criteria, bone marrow morphology, immunophe-
notyping and cytogenetics as both disorders are different
with respect to: modalities of treatment given, response to
therapy and prognosis [5-8]. The clinical presentation of
WM is similar to that of MM except that organomegaly is
common in WM but is uncommon in MM and that lytic
bony disease and renal disease are uncommon in WM but
are common in MM [5-8]. So far, less than fifty cases of
IgM myeloma have been reported. Ten percent of them
had serum creatinine greater than 20 mg/l and serum cal-
cium was greater than 120 mg/l in 24%. The mean serum
IgM level was 33 g/l and the mean medullary plasmocyto-
sis was 52%. Eighty per cent of the patients presented with
IgM kappa and only 20% with IgM lambda. Proteinuria
with light chains was found in 65% [5,9-12]. The cells in
IgM myeloma appear to be arrested at a point of matura-
tion between that of WM and MM. Preliminary data indi-
cate that a pattern of osteoclast-activating factor and
osteoprotegerin expression similar to that observed in
classic MM is present in IgM myeloma [5,9-12]. Even
though the cells of origin in WM and MM are mature and
heavily mutated cells, they differ in IgH gene rearrange-
ments. Especially in difficult cases of IgM MM, the search
for t (11; 14) may be useful to discriminate them from
WM [13,14]. The malignant cells in IgM myeloma have a
distinctive chromosomal translocation that differentiates
them from WM. These cells are post germinal-center in
origin with isotype-switch transcripts. IgM myeloma is
also characterized by negative CD20, D56 and CD117
phenotype and t(11;14) [13,14]. All the reported cases of
IgM myeloma had been treated with melphalan and pred-
nisolone with suboptimal results. Some patients were
treated with VAD (vincristine, Adriamycin and dexameth-
asone) regimen, others with CTD protocol. The results
were similar to the MP (melphalan and prednisolone)
regimen. Radiotherapy was mainly used as palliative
measure. Although elderly individuals are predominantly
affected by the disease as other types of myeloma, young
adults may rarely be affected. Eighty two per cent of
patients survive for one year. The estimated survival is
82% for 1 year, 62% for 2 years and 46% for 3 years. How-
ever, no prognostic factor has been found.
Conclusion
MM with IgM paraprotienaemia is a very rare disease,
which can present as any other type of myeloma. It should
be differentiated from WM. It is difficult to treat and the
results of the treatment are usually sub-optimal.
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